IT1400977B1 - Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. - Google Patents

Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.

Info

Publication number: IT1400977B1
Authority: IT; Italy
Prior art keywords: water; cyclodextrines; macrolide; ophthalmic; topical
Prior art date: 2010-07-01

Application number

ITMI2010A001212A

Other languages

English (en)

Inventor

Alberto Mangia

Elahi Shahrzad Reza

Riccardo Monti

Paride Grisenti

Elisa Verza

Original Assignee

Euticals Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-01

Filing date

2010-07-01

Publication date

2013-07-05

2010-07-01 Application filed by Euticals Spa filed Critical Euticals Spa

2010-07-01 Priority to ITMI2010A001212A priority Critical patent/IT1400977B1/it

2011-06-16 Priority to HUE11170078A priority patent/HUE025154T2/hu

2011-06-16 Priority to ES11170078.7T priority patent/ES2534989T3/es

2011-06-16 Priority to EP11170078.7A priority patent/EP2402350B1/en

2011-06-29 Priority to US13/172,038 priority patent/US9169269B2/en

2011-06-30 Priority to JP2011145736A priority patent/JP5856769B2/ja

2011-07-01 Priority to BRPI1103562-5A priority patent/BRPI1103562A2/pt

2012-01-02 Publication of ITMI20101212A1 publication Critical patent/ITMI20101212A1/it

2012-04-10 Priority to HK12103460.1A priority patent/HK1163068B/en

2013-07-05 Application granted granted Critical

2013-07-05 Publication of IT1400977B1 publication Critical patent/IT1400977B1/it

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 2
239000003120 macrolide antibiotic agent Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
230000000699 topical effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ITMI2010A001212A 2010-07-01 2010-07-01 Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine. IT1400977B1 (it)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
ITMI2010A001212A IT1400977B1 (it)	2010-07-01	2010-07-01	Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
HUE11170078A HUE025154T2 (hu)	2010-07-01	2011-06-16	Új vízoldható szilárd gyógyszerészeti zárványkomplexek és ezek vizes oldatai, orális, szemészeti, topikális vagy parenterális alkalmazásra, makrolidot és bizonyos ciklodextrineket tartalmazva
ES11170078.7T ES2534989T3 (es)	2010-07-01	2011-06-16	Nuevos complejos de inclusión farmacéuticos sólidos solubles en agua y sus soluciones acuosas para uso oral, oftálmico, tópico o parenteral que contienen un macrólido y ciertas ciclodextrinas
EP11170078.7A EP2402350B1 (en)	2010-07-01	2011-06-16	New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins.
US13/172,038 US9169269B2 (en)	2010-07-01	2011-06-29	Water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins
JP2011145736A JP5856769B2 (ja)	2010-07-01	2011-06-30	マクロライドおよびある特定のシクロデキストリンを含有する、経口、眼部、局所、または非経口使用のための新しい水溶性固体医薬包接複合体およびその水溶液
BRPI1103562-5A BRPI1103562A2 (pt)	2010-07-01	2011-07-01	Complexos de inclusão farmacêuticos sólidos solúveis em água e suas soluções aquosas para uso oral, oftálmico, tópico ou parenteral contendo um macrolídeo e certas ciclodextrinas
HK12103460.1A HK1163068B (en)	2010-07-01	2012-04-10	New water-soluble solid pharmaceutical inclusion complexes and their aqueous solutions for oral, ophthalmic, topical or parenteral use containing a macrolide and certain cyclodextrins

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ITMI2010A001212A IT1400977B1 (it)	2010-07-01	2010-07-01	Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.

Publications (2)

Publication Number	Publication Date
ITMI20101212A1 ITMI20101212A1 (it)	2012-01-02
IT1400977B1 true IT1400977B1 (it)	2013-07-05

Family

ID=43034339

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ITMI2010A001212A IT1400977B1 (it)	2010-07-01	2010-07-01	Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.

Country Status (7)

Country	Link
US (1)	US9169269B2 (it)
EP (1)	EP2402350B1 (it)
JP (1)	JP5856769B2 (it)
BR (1)	BRPI1103562A2 (it)
ES (1)	ES2534989T3 (it)
HU (1)	HUE025154T2 (it)
IT (1)	IT1400977B1 (it)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2014209141B2 (en)	2013-01-24	2018-05-10	Palvella Therapeutics, Inc.	Compositions for transdermal delivery of mTOR inhibitors
HUP1400075A2 (hu)	2014-02-14	2015-08-28	Druggability Technologies Ip Holdco Jersey Ltd	Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
EP3565520B1 (en)	2017-01-06	2026-02-25	Palvella Therapeutics, Inc.	Anhydrous compositions of mtor inhibitors and methods of use
EP3592367B1 (en) *	2017-03-07	2025-04-23	Roche Diagnostics GmbH	Stable formulations for immune-modulatory macrolides
CN107213470B (zh) *	2017-06-01	2020-05-19	中牧南京动物药业有限公司	酒石酸泰万菌素可溶性粉及其制备方法
US11000513B2 (en)	2018-07-02	2021-05-11	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
WO2023213731A1 (en)	2022-05-02	2023-11-09	Roche Diagnostics Gmbh	Hemolysis and derivatization reagents and methods for determining lactone analytes
TW202423434A (zh)	2022-10-07	2024-06-16	瑞士商歐庫利斯營運股份有限公司	mTOR抑制劑的點眼劑微懸液
CN117281951A (zh) *	2023-09-28	2023-12-26	瑞玞生物医学(深圳)有限公司	一种敷料及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5002935A (en)	1987-12-30	1991-03-26	University Of Florida	Improvements in redox systems for brain-targeted drug delivery
FR2736550B1 (fr) *	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
CA2553573A1 (en) *	2004-01-29	2005-08-11	Eisai R & D Management Co., Ltd.	Method for stabilizing macrolide compound
CA2578245C (en)	2004-08-27	2013-10-29	Cardinal Health 529, Llc	Solvent free amorphous rapamycin
MX2007003731A (es)	2004-09-29	2007-08-14	Johnson & Johnson	Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
WO2007011708A2 (en)	2005-07-15	2007-01-25	Micell Technologies, Inc.	Stent with polymer coating containing amorphous rapamycin
EP2135601A1 (en) *	2008-06-20	2009-12-23	Capsulution Nanoscience AG	Stabilization of amorphous drugs using sponge-like carrier matrices

2010
- 2010-07-01 IT ITMI2010A001212A patent/IT1400977B1/it active
2011
- 2011-06-16 EP EP11170078.7A patent/EP2402350B1/en active Active
- 2011-06-16 ES ES11170078.7T patent/ES2534989T3/es active Active
- 2011-06-16 HU HUE11170078A patent/HUE025154T2/hu unknown
- 2011-06-29 US US13/172,038 patent/US9169269B2/en active Active
- 2011-06-30 JP JP2011145736A patent/JP5856769B2/ja active Active
- 2011-07-01 BR BRPI1103562-5A patent/BRPI1103562A2/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
JP5856769B2 (ja)	2016-02-10
US20120053198A1 (en)	2012-03-01
ES2534989T3 (es)	2015-05-04
BRPI1103562A2 (pt)	2015-07-28
HUE025154T2 (hu)	2016-03-29
EP2402350B1 (en)	2015-01-28
JP2012031160A (ja)	2012-02-16
HK1163068A1 (en)	2012-09-07
ITMI20101212A1 (it)	2012-01-02
EP2402350A1 (en)	2012-01-04
US9169269B2 (en)	2015-10-27

Similar Documents

Publication	Publication Date	Title
IT1400977B1 (it)	2013-07-05	Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
NO2023023I1 (no)	2023-05-24	Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
LUC00083I2 (en)	2018-10-15	Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
EP2604612A4 (en)	2013-07-24	C-ARYL-GLUCOSIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF
BRPI1007446A2 (pt)	2016-09-06	formulações de fertilizante solúvel em água de dissolução rápida e métodos e usos das mesmas.
BR112013016772A2 (pt)	2016-10-11	composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
CL2014001729A1 (es)	2014-09-26	Compuestos derivados de tieno (3,2-d) pirimidina, inhibidores de quinasas; composicion farmaceutica; y su uso en la prevencion o tratamiento de una enfermedad relacionada con quinasas como cancer.
IL231386A (en)	2016-04-21	Pyrazolequinoline derivatives, their preparation and medical use
BRPI1008045A2 (pt)	2016-03-15	derivados de aminotetralina, composições farmacêuticas contendo-os, e seu uso em terapia
BRPI0918492A2 (pt)	2015-12-01	uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2481739A4 (en)	2013-02-27	DIHYDROPTERIDINONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL USE
PL2590975T3 (pl)	2016-01-29	Pochodne indolizyny, sposób ich wytwarzania i ich zastosowanie terapeutyczne
PL2655375T3 (pl)	2015-05-29	Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie
BR112014029705A2 (pt)	2017-06-27	composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
IT1403847B1 (it)	2013-11-08	Composizioni farmaceutiche comprendenti rifaximina e loro uso.
PT2736488E (pt)	2015-11-20	Composições farmacêuticas contendo rifaximina, processos para a sua preparação e sua utilização no tratamento de infeções vaginais
CL2013003230A1 (es)	2014-08-01	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
IT1398268B1 (it)	2013-02-22	Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
DK2816947T3 (da)	2022-07-11	Endoskopisk anordning, særlig til medicinsk brug
CL2008000444A1 (es)	2008-08-22	Quitosano, un derivado de quitosano soluble en agua y/o una sal del mismo para la aceleracion del ritmo de crecimiento de la una.
SI2448940T1 (sl)	2014-10-30	Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba
SMT201400168B (it)	2015-01-15	Composti di benzen.solfonammidi, loro procedimentodi sintesi e loro utilizzo in medicina
CL2013003198A1 (es)	2014-06-20	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
BR112014001425A2 (pt)	2017-11-21	forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
CL2014003484A1 (es)	2015-02-27	Uso de nalmefeno en la reduccion del consumo de alcohol en un paciente con dependencia del alcohol; composicion farmaceutica oral; combinacion farmaceutica.